Tesamorelin

Tesamorelin is a stabilized GHRH analog that amplifies your pituitary's own pulsatile GH release, raising IGF-1 ~80% while preserving physiological negative feedback (Falutz NEJM 2007). Exogenous recombinant GH, by contrast, bypasses the pituitary entirely and produces sustained supraphysiologic GH levels with no feedback suppression. That distinction matters because pulsatile, feedback-intact GH signaling is associated with a lower cancer-promotion signal than continuous HGH exposure, which has been linked in observational data to elevated colorectal cancer risk. Side effect profile also favors tesamorelin: less carpal tunnel, less edema, less insulin resistance at equivalent IGF-1 targets. Cost is higher on brand, mechanism is physiologically safer.

The FDA label for HIV-associated lipodystrophy is 2 mg subcutaneous daily in the evening (Falutz NEJM 2007, LIPO-010). Off-label biohacker protocols typically drop to 1 mg daily, injected 1 to 2 hours before bed to mimic the natural GH pulse that accompanies slow-wave sleep. Community cycling runs 12 to 16 weeks on, then 4 weeks off, to minimize somatotroph desensitization and preserve GHRH receptor sensitivity. Higher community doses of 3 to 4 mg daily exist but exceed clinical evidence by >2x and carry disproportionate glucose and edema risk without proven efficacy gains. Conservative users start at 1 mg, 5 days per week, to gauge tolerance.

Tesamorelin reduced visceral adipose tissue approximately 15% vs placebo at 26 weeks in Falutz NEJM 2007 (LIPO-010, n=412), the landmark Phase 3 that earned FDA approval. Cohen's d was ~0.55 to 0.70 on CT-measured VAT, a moderate-to-large clinically meaningful effect. Subcutaneous fat was preserved, which is the opposite of what caloric restriction does. Pooled Phase 3 data (Falutz AIDS 2008) and the 52-week extension (Falutz JAIDS 2010) confirmed durability across the dosing period. The effect requires continued dosing: VAT returns within ~26 weeks of discontinuation. Responder rate in the indicated population is approximately 70 to 75%.

Yes, substantially. Stanley et al. Lancet HIV 2019 randomized 61 adults with HIV and NAFLD to tesamorelin 2 mg/day vs placebo for 12 months. Relative liver fat fell ~32% in the tesamorelin arm (Cohen's d ~0.80 to 1.0), with reductions in hepatic fibrosis markers and improvements in ALT. The mechanistic follow-up in Fourman et al. JCI Insight 2020 showed reduced hepatic expression of fibrosis and inflammation genes on RNA-seq. No Phase 3 MASH trial in the general population has yet reported histologic endpoints, which is the main evidence gap. But the mechanism (GH-driven hepatic fat oxidation) and the HIV-NAFLD results both point toward meaningful off-label utility for metabolic liver disease.

Baker et al. Arch Neurol 2012 ran a 20-week RCT of tesamorelin 1 mg/day in 137 adults (healthy older adults and MCI). Results: improved executive function and verbal memory vs placebo, with Cohen's d ~0.30 to 0.40 (small-to-moderate). Friedman et al. JCEM 2013 followed with CSF biomarker data suggesting the cognitive signal traces to GH/IGF-1 restoration and downstream BDNF/synaptic support. This is a single trial without independent replication, which caps Evidence at 4.5 until confirmed. For adults with age-related cognitive complaints and low-normal baseline IGF-1, the signal is real but should not be treated as settled science the way VAT reduction can be.

Almost certainly yes, because the feedback-intact pulsatile release profile is fundamentally different from continuous supraphysiologic HGH. 52-week extension data (Falutz JAIDS 2010) showed sustained VAT reduction without emergent safety signals beyond arthralgia (~13%), injection-site reactions (~9 to 15%), peripheral edema (~6%), and transient glucose intolerance with modest HbA1c rise. IGF-1 elevation is mitogenic in principle, which makes active malignancy an absolute contraindication. Diabetic retinopathy worsening is a class concern. No long-term cancer incidence signal has emerged in 15 years of post-market surveillance. For people without cancer history, the net safety profile is meaningfully better than HGH at equivalent IGF-1 targets.

Brand Egrifta SV runs $3,000 to $4,000/month retail, which is the single biggest accessibility barrier. The FDA has ruled tesamorelin ineligible for 503A/503B compounding because an approved product is commercially available, which legally closes the pharmacy compounding path that semaglutide briefly had during shortages. Some clinics dispense lower-priced compounded tesamorelin ($150 to $300/month), but that supply originates from research-peptide channels with inconsistent identity, mass accuracy, and endotoxin testing. This is extrinsic supply-chain risk, not a property of the molecule itself, and belongs in sourcing decisions rather than the safety score. Verified-source sourcing is essential.

Evening injection 1 to 2 hours before bed is standard because endogenous GH release peaks during slow-wave sleep, and tesamorelin is designed to amplify that natural pulse rather than fight it. Morning dosing reduces the sleep-architecture benefit and blunts the circadian IGF-1 rise. Community stacking with CJC-1295 (longer-half-life GHRH analog) is redundant mechanistically, since both hit the GHRH receptor. A more rational stack is tesamorelin (GHRH side) plus ipamorelin or a ghrelin mimetic (GHRP side), which activates a parallel pathway and theoretically produces larger, more physiologic GH pulses. No RCT supports stacked dosing; all stacking evidence is community-grade.